Surface tunability of nanoparticles in modulating platelet functions

Blood Cells, Molecules, and Diseases

Volumn 48, Issue 1, 2012, Pages 36-44

  Deb, Suryyani ^a   Raja, S O ^a   Dasgupta, Anjan Kr ^a   Sarkar, Rajkumar ^b   Chattopadhyay, Asoke P ^b   Chaudhuri, Utpal ^c   Guha, Pradipta ^c   Sardar, Partha ^c  

^a UNIVERSITY OF CALCUTTA   (India)

^b UNIVERSITY OF KALYANI   (India)

^c MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Antiplatelet; Inert; Metallic nanoparticle; Proaggregatory; Surface functionalization

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADRENALIN; CITRIC ACID; CLOPIDOGREL; COLLAGEN; FIBRINOGEN RECEPTOR; GOLD NANOPARTICLE; IRON OXIDE NANOPARTICLE; METAL NANOPARTICLE; PADGEM PROTEIN; SILVER NANOPARTICLE; THROMBIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; CELL GRANULE; CONJUGATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LOADING DRUG DOSE; NANOPARTICLE SURFACE CAPPING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADENOSINE TRIPHOSPHATE; ASPIRIN; BLOOD PLATELETS; BLOTTING, WESTERN; CITRIC ACID; COATED MATERIALS, BIOCOMPATIBLE; FERRIC COMPOUNDS; FLOW CYTOMETRY; GOLD; HUMANS; METAL NANOPARTICLES; MICROSCOPY, ATOMIC FORCE; NANOTECHNOLOGY; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SILVER; STARCH; SURFACE PROPERTIES;

EID: 84855194953     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.09.011     Document Type: Article

References (25)

1. Rodvien R., Mielke C.H. Role of platelets in hemostasis and thrombosis. West. J. Med. 1976, 125(3):181-186.
2. Hossain N., Farzana T., Khan N.H., Shamsi T.S., James A.H. Adolescent menorrhagia due to platelet function disorder. J. Pak. Med. Assoc. 2010, 60(2):127-129.
3. Lahiri P., Chaudhuri U., Chattopadhyay A., Chakraborty P., Mandal D., Dasgupta A.K. Structural insights in platelet receptor synergism-antiplatelet therapy in post-ischemic cerebrovascular events. Blood Cells Mol. Dis. 2005, 34(3):248-256.
4. Lahiri P., Roy S., Sardar P., Deb S., Chakrabarti P., Guha P., Guha S., Chaudhuri U., Dasgupta A.K. Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome. Blood Cells Mol. Dis. 2009, 43(1):105-110.
5. Patra H.K., Banerjee S., Chaudhuri U., Lahiri P., Dasgupta A.K. Cell selective response to gold nanoparticle. Nanomedicine 2007, 3(2):111-119.
6. Lara H.H., Ayala-Nuñez N.V., Ixtepan-Turrent L., Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010, 8(1).
7. Pissuwan D., Niidome T., Cortie M.B. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J. Control. Release 2007, 149(1):65-71.
8. Chauvierre C., Vauthier C., Labarre D., Couvreur P., Marden M.C., Leclerc.L. A new generation of polymer nanoparticles for drug delivery. Cell. Mol. Biol. 2004, 50(3):233-239. (Noisy-le-grand).
9. Choi H., Choi S.R., Zhou R., Kung H.F., Chen I.W. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad. Radiol. 2004, 11(9):996-1004.
10. Geys J., Nemmar A., Verbeken E., Smolders E., Ratoi M., Hoylaerts M.F., Nemery B., Hoet P.H. Acute toxicity and prothrombotic effects of quantum dots: impact of surface charge. Environ. Health Perspect. 2008, 116(12):1607-1613.
11. Oberdrster G., Stone V., Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 2007, 1:2-25.
12. Deb S., Chatterjee M., Bhattacharya J., Lahiri P., Chaudhuri U., PalChoudhuri S., Kar S., Siwach O.P., Sen P., Dasgupta A.K. Role of purinergic receptors in platelet-nanoparticle interactions. Nanotoxicology 2007, 1:93-103.
13. Deb S., Patra H.K., Lahiri P., Dasgupta A.K., Chakrabarti K., Chaudhuri U. Multistability in platelets and their response to gold nanoparticles. Nanomedicine 2011, 7(4):376-384.
14. Wiwanitkit V., Sereemaspun A., Rojanathanes R. Gold nanoparticles and a microscopic view of platelets: a preliminary observation. Cardiovasc. J. Afr. 2009, 20(2):141-142.
15. Radomski A., Jurasz P., Alonso-Escolano D., Drews M., Morandi M., Malinski T., Radomski M.W. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 2005, 146(6):882-893.
16. Shrivastava S., Bera T., Singh S.K., Singh G., Ramachandrarao P., Dash D. Characterization of antiplatelet properties of silver nanoparticles. ACS Nano 2009, 3:1357-1364.
17. Jiang J.S., Gan Z.F., YanG Y., Du B., Qian M., Zhang P. A novel magnetic fluid based on starch-coated magnetite nanoparticles functionalized with homing peptide. J Nanopart Res. 2009, 11(6):1321-1330.
18. Roy S., Basak S., Dasgupta A.K. Nanoparticle induced conformational change in DNA and chirality of silver nanoclusters. J. Nanosci. Nanotechnol. 2010, 10(2):819-825.
19. McGuinnes C., Duffin R., Brown S.L., Mills N., Megson I.L., Macnee W., Johnston S., Lu S.L., Tran L., Li R., Wang X., Newby D.E., Donaldson K. Surface derivatization state of polystyrene latex nanoparticles determines both their potency and their mechanism of causing human platelet aggregation in vitro. Toxicol. Sci. 2011, 119(2):359-368.
20. Miller V.M., Hunter L.W., Chu K., Kaul V., Squillace P.D., Lieske J.C., Jayachandran M. Biologic nanoparticles and platelet reactivity. Nanomedicine (Lond.) 2009, 4(7):725-733.
21. Kaplan S., Kaplan A., Marcoe K., Sauvage L.R. Ticlopidine, Alka-Seltzer, or a combination of citric acid with aspirin: effects on platelet aggregation in individuals with an insufficient response to aspirin alone. Clin. Appl. Thromb. Hemost. 2000, 6(4):222-225.
22. L.R. Sauvage, S. Kaplan, A. Kaplan, Method for reducing platelet aggregation. Application Number: 08/052219. Publication Date: 03/28/1995. Filing Date: 04/22/1993.
23. Cuisset T., Quilici J., Fugon L., Cohen W., Roux P., Gaborit B., Molines L., Fourcade L., Bonnet J.L., Carrieri P. Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. Arch. Cardiovasc. Dis. 2011, 104(5):306-312.
24. Guthikonda S., Lev E.I., Patel R., DeLao T., Bergeron A.L., Dong J.F., Kleiman N.S. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J. Thromb. Haemost. 2007, 5(3):490-496.
25. White J.G. Platelets are covercytes, not phagocytes: uptake of bacteria involves channels of the open canalicular system. Platelets 2005, 16(2):121-131.